AR065554A1 - Formas cristalinas de un compuesto 8- azabiciclo (3,2,1) octano. procesos de obtencion y composiciones farmaceuticas. - Google Patents

Formas cristalinas de un compuesto 8- azabiciclo (3,2,1) octano. procesos de obtencion y composiciones farmaceuticas.

Info

Publication number
AR065554A1
AR065554A1 ARP080100850A ARP080100850A AR065554A1 AR 065554 A1 AR065554 A1 AR 065554A1 AR P080100850 A ARP080100850 A AR P080100850A AR P080100850 A ARP080100850 A AR P080100850A AR 065554 A1 AR065554 A1 AR 065554A1
Authority
AR
Argentina
Prior art keywords
crystalline salt
pharmaceutical compositions
processes
azabiciclo
octano
Prior art date
Application number
ARP080100850A
Other languages
English (en)
Spanish (es)
Inventor
Sean M Dalziel
Miroslav Rapta
Leticia M Preza
Pierre-Jean Colson
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39620376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065554(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of AR065554A1 publication Critical patent/AR065554A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP080100850A 2007-02-28 2008-02-28 Formas cristalinas de un compuesto 8- azabiciclo (3,2,1) octano. procesos de obtencion y composiciones farmaceuticas. AR065554A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90409007P 2007-02-28 2007-02-28
PCT/US2008/002583 WO2008106159A1 (en) 2007-02-28 2008-02-27 Crystalline forms of an 8-azabicyclo[3.2.1]octane compound

Publications (1)

Publication Number Publication Date
AR065554A1 true AR065554A1 (es) 2009-06-17

Family

ID=39620376

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080100850A AR065554A1 (es) 2007-02-28 2008-02-28 Formas cristalinas de un compuesto 8- azabiciclo (3,2,1) octano. procesos de obtencion y composiciones farmaceuticas.
ARP170102183A AR109224A2 (es) 2007-02-28 2017-07-31 Formas de sales cristalinas de un compuesto 8-azabiciclo[3,2,1]octano, composición farmacéutica que las comprende, procesos para prepararlas, compuesto intermediario de síntesis relacionado y su uso para la fabricación de un medicamento

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170102183A AR109224A2 (es) 2007-02-28 2017-07-31 Formas de sales cristalinas de un compuesto 8-azabiciclo[3,2,1]octano, composición farmacéutica que las comprende, procesos para prepararlas, compuesto intermediario de síntesis relacionado y su uso para la fabricación de un medicamento

Country Status (26)

Country Link
US (7) US7943772B2 (https=)
EP (1) EP2132204B1 (https=)
JP (2) JP5512289B2 (https=)
KR (1) KR101480530B1 (https=)
CN (1) CN101616916B (https=)
AR (2) AR065554A1 (https=)
AU (1) AU2008219615B2 (https=)
BR (1) BRPI0807974B8 (https=)
CA (1) CA2678073C (https=)
CL (1) CL2008000573A1 (https=)
CO (1) CO6220856A2 (https=)
CY (1) CY1115077T1 (https=)
DK (1) DK2132204T3 (https=)
ES (1) ES2402031T3 (https=)
HR (1) HRP20130193T1 (https=)
IL (1) IL200131A (https=)
MX (1) MX2009009141A (https=)
MY (1) MY148318A (https=)
NZ (1) NZ578871A (https=)
PL (1) PL2132204T3 (https=)
PT (1) PT2132204E (https=)
RU (1) RU2458061C2 (https=)
SI (1) SI2132204T1 (https=)
TW (1) TWI409067B (https=)
WO (1) WO2008106159A1 (https=)
ZA (1) ZA200905832B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
TWI415850B (zh) * 2007-07-20 2013-11-21 Theravance Inc 製備ｍｕ類鴉片受體拮抗劑之中間物的方法
US7691878B2 (en) * 2007-08-27 2010-04-06 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI423801B (zh) * 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
US7947710B2 (en) * 2007-08-27 2011-05-24 Theravance, Inc. Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
WO2009029252A1 (en) * 2007-08-27 2009-03-05 Theravance, Inc. Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
AU2010295464B2 (en) * 2009-09-18 2015-11-26 Merck Sharp & Dohme Corp. Use of opioid receptor antagonist for gastrointestinal tract disorders
DK3277278T3 (da) 2015-04-02 2020-04-06 Theravance Biopharma R&D Ip Llc Kombinationsdoseringsform af en my-opioid receptorantagonist og et opioid

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5159081A (en) 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US6900228B1 (en) 1998-03-10 2005-05-31 Research Triangle Institute Opiate compounds, methods of making and methods of use
GB9810671D0 (en) 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
TWI244481B (en) 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6467084B1 (en) * 1999-12-16 2002-10-15 Emware, Inc. Systems and methods for reprogramming an embedded device with program code using relocatable program code
EP1263758A2 (en) 2000-03-03 2002-12-11 Ortho-McNeil Pharmaceutical, Inc. 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
US20020025948A1 (en) 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
EP1440059B1 (en) 2001-10-22 2008-04-16 Pfizer Products Inc. 3-azabicyclo(3.1.0)hexane derivatives as opioid receptor antagonists
US7381721B2 (en) 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
US20040204453A1 (en) 2003-04-14 2004-10-14 Pfizer Inc 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
BRPI0409307A (pt) * 2003-04-14 2006-04-25 Pfizer Prod Inc derivados de 3-azabiciclo[3.2.1]octano
US7056930B2 (en) 2003-04-14 2006-06-06 Pfizer Inc. 2-Azabicyclo[3.3.1]nonane derivatives
CA2522199A1 (en) 2003-04-15 2004-10-28 Pfizer Products Inc. 3-benzhydrylidene-8-aza-bicyclo¬3.2.1|octane derivatives with opioid receptor activity
US6992090B2 (en) 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
EP1737853A1 (en) 2004-02-03 2007-01-03 Janssen Pharmaceutica N.V. 3-(diheteroarylmethylene)-8-azabicyclo¬3.2.1|octane and 3-((aryl)(heteroaryl)methylene)-8-azabicyclo¬3.2.1|octane derivatives
US7087749B2 (en) 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
JP2010509227A (ja) 2006-11-07 2010-03-25 ネクター セラピューティックス エイエル，コーポレイション オピオイド作動薬およびオピオイド拮抗薬の用量形態および同時投与
TWI409067B (zh) 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型

Also Published As

Publication number Publication date
NZ578871A (en) 2012-01-12
US20110184008A1 (en) 2011-07-28
DK2132204T3 (da) 2013-04-29
MY148318A (en) 2013-03-29
US8247555B2 (en) 2012-08-21
ES2402031T3 (es) 2013-04-26
US20130072515A1 (en) 2013-03-21
TW200845984A (en) 2008-12-01
MX2009009141A (es) 2009-09-03
CA2678073C (en) 2016-01-05
CN101616916A (zh) 2009-12-30
RU2009135834A (ru) 2011-04-10
US20150073014A1 (en) 2015-03-12
US8816091B2 (en) 2014-08-26
US20080207676A1 (en) 2008-08-28
US20160287572A1 (en) 2016-10-06
RU2458061C2 (ru) 2012-08-10
IL200131A0 (en) 2010-04-15
BRPI0807974A2 (pt) 2014-09-16
US8536335B2 (en) 2013-09-17
KR20090115767A (ko) 2009-11-05
CL2008000573A1 (es) 2008-05-16
US20140080856A1 (en) 2014-03-20
JP5512289B2 (ja) 2014-06-04
ZA200905832B (en) 2010-05-26
CY1115077T1 (el) 2016-12-14
EP2132204A1 (en) 2009-12-16
AU2008219615B2 (en) 2013-05-09
BRPI0807974B1 (pt) 2020-11-24
JP2013151564A (ja) 2013-08-08
EP2132204B1 (en) 2013-01-23
IL200131A (en) 2013-03-24
US20180200246A1 (en) 2018-07-19
JP2010520198A (ja) 2010-06-10
PT2132204E (pt) 2013-03-25
AU2008219615A1 (en) 2008-09-04
WO2008106159A1 (en) 2008-09-04
AR109224A2 (es) 2018-11-07
BRPI0807974B8 (pt) 2021-05-25
SI2132204T1 (sl) 2013-05-31
US10426766B2 (en) 2019-10-01
PL2132204T3 (pl) 2013-06-28
HK1139399A1 (en) 2010-09-17
US9949963B2 (en) 2018-04-24
KR101480530B1 (ko) 2015-01-08
US9290491B2 (en) 2016-03-22
CO6220856A2 (es) 2010-11-19
CA2678073A1 (en) 2008-09-04
TWI409067B (zh) 2013-09-21
US7943772B2 (en) 2011-05-17
HRP20130193T1 (hr) 2013-03-31
CN101616916B (zh) 2011-10-12

Similar Documents

Publication Publication Date Title
AR065554A1 (es) Formas cristalinas de un compuesto 8- azabiciclo (3,2,1) octano. procesos de obtencion y composiciones farmaceuticas.
AR106702A2 (es) Uso de un anticuerpo antagonista anti-ngf para la preparación de un medicamento
UY27720A1 (es) Aroilpiridinonas monocíclicas,
AR065083A1 (es) Hepcidina, antagonistas de la hepcidina y metodos de uso
CL2012003632A1 (es) Compuestos derivados de pirazolo[1,5-a]pirimidinas o una sal farmaceuticamente aceptable de los mismos; composicion farmaceutica que los comprende; y su uso para tratar una infeccion por virus pneumovirinae o una infeccion por virus sincicial respiratorio.
PE20121179A1 (es) Forma cristalina de hemifumarato de alisquireno
CR20150401A (es) Formas de rifaximina y sus usos
CL2011000973A1 (es) Compuestos derivados de pirazolo [1,5-a]pirimidina3-cabroxamida; composicion farmaceutica que los comprende, y uso para tratar o disminuir la gravedad de una enfermedad o condicion que responde a la inhibicion de la actividad de una jak quinasa.
BR112013009117A2 (pt) sal tosilato de (8s,9r)-5-fluor-8-(4-fluorefenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-diidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona, método para preparar uma forma cristalina e uso do mesmo,composição farmacêutica e método para tratar um câncer ou um sintoma do mesmo.
BRPI0818193A2 (pt) composto, sal farmacêuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto
AR088755A1 (es) Formas solidas de un inhibidor de disociacion transtiretina
AR077203A1 (es) Forma polimorfica d del acetato de bazedoxifeno, composiciones farmaceuticas que la contienen metodo para prepararla y uso del mismo para tratar enfermedades mediadas por moduladores selectivos de receptores estrogenicos (serms)
PA8800701A1 (es) Sales de maleato de [e]-n-{4-[3-cloro-4-[2-piridinilmetoxi]anilino]-3-ciano-7-etoxi-6-quinolinil}-4-[dimetilamino]-2-butenamide, sus formas cristalinas, procesos para su preparacion, y metodos para su uso
PE20140698A1 (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2, 4-diamina
ECSP055699A (es) Indazoles, benzotiazoles y benzoisotiazoles, y su preparacion y usos
CR20120620A (es) Nuevas formas de rifaximina y usos de las mismas
UY31456A1 (es) Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos
CL2007003472A1 (es) Sal fumarato de (alfa s,beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol; proceso de preparacion; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamie
AR124497A2 (es) Métodos para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos métodos, y composición farmacéutica
ECSP045484A (es) Derivados de carbamato de quinuclidina
CL2007003346A1 (es) Compuestos derivados de 2,5-dihidro-3h-pirazolo[4,3-c]piridazin-3-ona; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome de abstinencia a una sustancia, tras
BR112013020265A2 (pt) formas de rifaximina e uso das mesmas
BRPI0914912A2 (pt) processo para a preparação de um composto, e de um inibidor de mtor quinase, sal de fumarato, composição farmacêutica, uso de um sal de fumarato, e, métodos para produzir um efeito inibitório mtor, e para produzir um efeito anti-câncer em um animal de sangue quente
BRPI0912267A2 (pt) sal farmaceuticamente aceitável, composição farmacêutica, artigo de fabricação, métodos para tratar asma, rinite alérgica, doença, lesões gástricas e dor, métodos para prevenir broncoconstrição e rinite alérgica, uso de um sal farmaceuticamente aceitável, e, processo para a preparação de um sal farmaceuticamente aceitável.
PE20130212A1 (es) Formas polimorficas de st-246 y metodos de preparacion

Legal Events

Date Code Title Description
FC Refusal